Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Ecstasy: dangers and controversies.

J V Pham1, T Puzantian

  • 1School of Pharmacy, University of California-San Francisco, USA.

Pharmacotherapy
|January 5, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Psychiatric pharmacists.

The American journal of psychiatry·2001
Same author

Prediction of valproate serum concentrations in adult psychiatric patients using Bayesian model estimations with NPEM2 population pharmacokinetic parameters.

Therapeutic drug monitoring·1999
Same author

Does the addition of pindolol accelerate or enhance the response to selective serotonin reuptake inhibitor antidepressants?

Pharmacotherapy·1999
Same author

Mirtazapine, an antidepressant.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1998
Same author

Nefazodone and symptoms suggesting neurotoxicity: a case report.

The Journal of clinical psychiatry·1996
Same author

Criteria for use of valproate in adult psychiatric inpatients and outpatients.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1996
Same journal

The Effect of Multiple Doses of Itraconazole on the Pharmacokinetics of a Single Oral Dose of Zongertinib in Healthy Male Volunteers.

Pharmacotherapy·2026
Same journal

Menopausal Hormone Therapy: A Narrative Review of Contemporary Evidence.

Pharmacotherapy·2026
Same journal

Getting It Right the Second Time: How Can we Optimize First-Generation Cephalosporin Dosing for Skin and Soft Tissue Infections in the 21st Century?

Pharmacotherapy·2026
Same journal

Buprenorphine Initiation During Extracorporeal Membrane Oxygenation Decreases Sedative and Opioid Exposure: A Retrospective Matched Case-Control Study.

Pharmacotherapy·2026
Same journal

Voriconazole Dosing and Therapeutic Drug Monitoring in Patients Before and After Liver Transplantation.

Pharmacotherapy·2026
Same journal

Quantifying the Serum Magnesium Response and Predictors of Response Following Intravenous Magnesium Replacement in Critically Ill Patients.

Pharmacotherapy·2026
See all related articles

Ecstasy, a popular recreational drug among adolescents, poses significant health risks despite its perceived safety. Adverse effects range from hyperthermia and seizures to long-term cognitive and psychiatric issues due to serotonin depletion.

Area of Science:

  • Neuroscience
  • Toxicology
  • Adolescent Medicine

Background:

  • Ecstasy (MDMA) is a recreational drug gaining popularity, especially among young adolescents.
  • Its appeal stems from euphoric and empathogenic effects, often accompanied by a false perception of safety.
  • Increasing reports highlight adverse effects, toxic reactions, and fatalities associated with its use.

Purpose of the Study:

  • To review the adverse effects and potential long-term consequences of recreational Ecstasy use.
  • To address the discrepancy between perceived safety and documented health risks.
  • To inform medical professionals and the public about the dangers of Ecstasy.

Main Methods:

  • Literature review of medical case reports and popular press articles on Ecstasy-related incidents.

Related Experiment Videos

  • Analysis of documented adverse effects and toxicological findings.
  • Examination of studies on the neurotoxicological impact of MDMA on serotonin systems.

    • Main Results:

    • Adverse effects include hyperthermia, seizures, cardiac abnormalities, and hyponatremia.
    • Long-term use is linked to serotonin terminal degeneration and depletion.
    • These neurotoxic changes may lead to psychiatric and cognitive sequelae.
    • Fatalities and severe toxic reactions are increasingly reported.

    Conclusions:

    • Ecstasy use carries substantial health risks, contradicting its perception as a safe recreational drug.
    • The neurotoxic effects of Ecstasy on serotonin pathways can result in lasting psychiatric and cognitive impairments.
    • Further research and public health awareness are crucial to mitigate the harms associated with Ecstasy use.